WAVEMAN · COMPANY
VRXA · Veraxa Biotech Ag - Post De-Spac
> Search tickers & screens ⌘K
LIVE
TEAM-1.45% 13F +439META-4.79% 13F +2,704RCG-1.64% CLUSTERUTHR-0.84% 13F +428CRWV-2.88% 13F +696CRM-2.88% 13F +1,024CVNA-7.06% 13F +799DELL-3.46% 13F +1,209TPL-2.79% 13F +443NET+1.42% 13F +713MSTR-0.93% 13F +526CRWD+2.82% 13F +1,386ANET-1.01% 13F +1,327COIN-1.70% 13F +475TEAM-1.45% 13F +439META-4.79% 13F +2,704RCG-1.64% CLUSTERUTHR-0.84% 13F +428CRWV-2.88% 13F +696CRM-2.88% 13F +1,024CVNA-7.06% 13F +799DELL-3.46% 13F +1,209TPL-2.79% 13F +443NET+1.42% 13F +713MSTR-0.93% 13F +526CRWD+2.82% 13F +1,386ANET-1.01% 13F +1,327COIN-1.70% 13F +475
← ALL COMPANIES

VRXA

Veraxa Biotech AG - Post de-SPAC
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0002079109
Quote by TradingView
CLUSTER · 3 INSIDERSACTIVIST 13DC-SUITE BUYING · 1☆ WATCH
INSIDER NET · 180D
$92.7K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
3
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter

WaveMan Stock Sonar 2/7 axesFind similar shapesCompare

Insider conviction
82
inputs
  • Net open-market buying, 180d$93K · 75 pct, sector of 440
  • Insider buyers, 180d3 · 89 pct, sector of 445
Risk and compliance
55
inputs
  • Short interest, % of float+5.5% · 55 pct, sector of 815
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Growth, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 0 present: not filed
  • Financial health needs 1 of 2 inputs, 0 present: not filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored, each a percentile against sector peers (universe where the sector is thin). Higher is better on every axis; an unscored axis is unmeasured, not a low score. How it is scored

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$92.7K over 180 days
+$92.7K over 90 days
more than 75% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
5.5% of the float short (float per yahoo 2026-09-29) · 1.0 days to cover · settled 2026-09-15
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
3 insiders independently bought a net $92.7K, no planned sales are queued against it.
Deck David Lukas disclosed a 5%+ stake (18.0%) in the last six months.

Watch VRXA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Email me when insiders trade VRXA
Live price
Daily candles from TradingView, on their licence , no filings are marked on this one
WHY THIS NAME IS ON THE DESK
3 insiders reported buying shares.
The record shows a net $92.7K bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLINSM
Insider transactions
Form 4 purchases and sales (codes P and S), grants, option exercises and preferred conversions excluded

Over the last 180 days, Veraxa Biotech AG - Post de-SPAC insiders bought a net $92.7K of stock across 3 Form 4 purchases and sales, with 3 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-30.

INSIDER
FILED
SHARES
VALUE
Hosseinion Warren
Director
BUY
2026-09-10
6,024
$10.1K
Antz Christoph Rudiger
Chief Executive Officer
BUY
2026-08-27
5,000
$7.7K
Baumann Oliver Rolf
Director
BUY
2026-08-27
50,000
$75.0K
3 TRANSACTIONS ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to use the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

5%+ owners
13D = intent to influence · 13G = passive
Deck David Lukas
ACTIVIST 13D · 2026-06-16
18.0%
European Molecular Biology Laboratory
ACTIVIST 13D · 2026-06-16
16.2%
Schoeni Gilbert Edgar
ACTIVIST 13D · 2026-06-15
15.9%
Xlife Sciences AG
ACTIVIST 13D · 2026-06-15
16.3%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.